Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Spagnolo

Showing results (61-70 of 116) with videos related to

Pageof 12
Sort By:
Oncotarget|January 1, 2017
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistryWilliam Bruno, Claudia Martinuzzi, Virginia Andreotti, et al.
International Journal of Cancer|August 4, 2019
HO-1 downregulation favors BRAF<sup>V600</sup> melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognitionAnna L Furfaro, Selene Ottonello, Giulia Loi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysisAndrea Boutros, Enrica Teresa Tanda, Elena Croce, et al.
Clinical Immunology (Orlando, Fla.)|April 29, 2020
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to IpilimumabMaria Pia Pistillo, Roberta Carosio, Federica Grillo, et al.
Journal of Translational Medicine|February 15, 2020
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patientsGiulia Ciccarese, Bruna Dalmasso, William Bruno, et al.
Biomedicines|December 23, 2022
Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control StudyAntonio Cimellaro, Desirée Addesi, Michela Cavallo, et al.
Oncotarget|March 20, 2018
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenibPaola Queirolo, Francesco Spagnolo, Virginia Picasso, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2020
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4<sup>+</sup> tumor infiltrating lymphocytes and their in situ localizationLuca Mastracci, Vincenzo Fontana, Paola Queirolo, et al.
Pigment Cell & Melanoma Research|August 16, 2014
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasionRosaria Gangemi, Adriana Amaro, Alice Gino, et al.
Oncotarget|March 20, 2018
Current status and perspectives in immunotherapy for metastatic melanomaRiccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, et al.
Pageof 12

Showing results (61-70 of 116) with videos related to

Sort By:
Pageof 12
Oncotarget|January 1, 2017
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistryWilliam Bruno, Claudia Martinuzzi, Virginia Andreotti, et al.
International Journal of Cancer|August 4, 2019
HO-1 downregulation favors BRAF<sup>V600</sup> melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognitionAnna L Furfaro, Selene Ottonello, Giulia Loi, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysisAndrea Boutros, Enrica Teresa Tanda, Elena Croce, et al.
Clinical Immunology (Orlando, Fla.)|April 29, 2020
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to IpilimumabMaria Pia Pistillo, Roberta Carosio, Federica Grillo, et al.
Journal of Translational Medicine|February 15, 2020
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patientsGiulia Ciccarese, Bruna Dalmasso, William Bruno, et al.
Biomedicines|December 23, 2022
Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control StudyAntonio Cimellaro, Desirée Addesi, Michela Cavallo, et al.
Oncotarget|March 20, 2018
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenibPaola Queirolo, Francesco Spagnolo, Virginia Picasso, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2020
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4<sup>+</sup> tumor infiltrating lymphocytes and their in situ localizationLuca Mastracci, Vincenzo Fontana, Paola Queirolo, et al.
Pigment Cell & Melanoma Research|August 16, 2014
ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasionRosaria Gangemi, Adriana Amaro, Alice Gino, et al.
Oncotarget|March 20, 2018
Current status and perspectives in immunotherapy for metastatic melanomaRiccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, et al.
Pageof 12